DLL4 and hereditary elliptocytosis: Importantly, the phenotypes of blocking DLL4 with an antibody or treatment with γ-secretase inhibitors is dependent on the developmental stage of HE and HSPC; blocking DLL4 ex vivo most efficiently increases HSC activity when applied at early AGM stages (31–34 s)17.